Cargando…
Native Mass Spectrometry for the Study of PROTAC GNE‐987‐Containing Ternary Complexes
PROteolysis TArgeting Chimeras (PROTACs) promote the degradation, rather than inhibition, of a drug target as a mechanism for therapeutic treatment. Bifunctional PROTAC molecules allow simultaneous binding of both the target protein and an E3‐Ubiquitin ligase, bringing the two proteins into close sp...
Autores principales: | Sternicki, Louise M., Nonomiya, Jim, Liu, Miaomiao, Mulvihill, Melinda M., Quinn, Ronald J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359942/ https://www.ncbi.nlm.nih.gov/pubmed/33792163 http://dx.doi.org/10.1002/cmdc.202100113 |
Ejemplares similares
-
BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma
por: Chen, Yan-Ling, et al.
Publicado: (2022) -
Native Mass Spectrometry Can Effectively Predict PROTAC
Efficacy
por: Beveridge, Rebecca, et al.
Publicado: (2020) -
An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16
por: Ma, Liya, et al.
Publicado: (2022) -
BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia
por: Sang, Xu, et al.
Publicado: (2022) -
Development of a target identification approach using native mass spectrometry
por: Liu, Miaomiao, et al.
Publicado: (2021)